Here are some medtech stories we missed this week but thought were still worth mentioning.
1. AMNIOX touts new umbilical cord study
AMNIOX Medical announced that it has published the results of 3 studies that demonstrate the effectiveness of umbilical cord tissue for treating chronic wounds, according to an April 7 press release. The company’s cryopreserved human umbilical cord tissue, NEOX Cord 1K was tested on 29 patients who needed a wound allograft to treat chronic diabetic foot ulcers. Twenty-eight of the 32 wounds showed complete healing with a success rate of 87.5%. In another test, 57 patients with chronic, lower-extremity ulcers received the treatment. Fifty-one out of 64 wounds with a healing rate of 79.7% had complete healing. The third study tested 31 patients who had lower extremity ulcers with exposed bone, tendon, muscle or joint capsule with underlying osteomyelitis. Twenty-six out of 33 wounds had completely healed, resulting in a healing rate of 78%.
2. InVivo Therapeutics enrolls another patient in study
InVivo Therapeutics announced in an April 5 press release that it has enrolled a new patient into its Inspire study that is meant to test the benefits of the Neuro-Spinal Scaffold. The surgery was performed on the patient 42 hours after injury at the Carolinas Medical Center in Charlotte, N.C. The addition of this patient makes the total of enrolled patients 14. The Neuro-Spinal Scaffold is designed to support appositional healing and reduce post-traumatic cavity formation while sparing white matter and allowing for neural regeneration across the healed wound epicenter.
3. Occlutech receives CE Mark
Occlutech has received European CE Mark for its Perimembranous Ventricular Septal Defect (PmVSD) Occluder, according to an April 5 press release. The PmVSD is an implant that is designed for the minimally invasive closure of perimembranous ventricular septal defects. It is made with a flexible nitinol wire mesh with shape memory properties.
4. Cianna Medical announces new data for Scout radar localization system
Cianna Medical announced in an April 6 press release that data from its Scout radar localization system has been proven to be clinically equivalent to radio seed localization for surgical targeting of non-palpable breast lesions. There were 119 patients in the study who went through breast conserving therapy using the Scout radar localization or RSL, which uses a radioactive seed to target tumors. The study showed that the average volume of resection and repeats surgery rates were about equal with successful removal of markers. Scout is a zero-radiation, wire-free solution for breast tumor localization. It is FDA-cleared and is smaller than a grain of rice. Scout uses a highly-sophisticated reflector that is placed at the tumor site 30 days before a lumpectomy or surgical biopsy. The surgeon then scans the breast during the procedure using the Scout guide that emits 50 million pulses per second.
5. AngioDynamics announces pricing of secondary offering
AngioDynamics announced the pricing of its previously announced underwritten public offering by its stockholders in an April 6 press release. It is offering 2.35 million shares of its common stock at a public price of $16.20 per share. The selling stockholders will receive the net proceeds from the offering. The company is not selling shares. Barclays Capital is the sole underwriter of the offering.
6. Nu-Med selects advisors to valuate company
Nu-Med Plus has chosen Houlihan Advisors for an independent company valuation, according to an April 5 press release. Nu-Med Plus has garnered a lot of technical know-how, intellectual property and has developed multiple products as a research and development company. Houlihan Advisors will be providing a current valuation of all of its assets.
7. Aesculap launches novel spine device warranty
Aesculap Implant Systems announced in an April 6 press release that it has created a new warranty program on its established portfolio of surface-enhanced interbodies for spinal fusion. The warranty gives participating facilities a device replacement in the case of a reiteration because of clinically-relevant delamination or the generation of impaction debris or a CT or MRI artifact caused by a device that reduces the physician’s ability to see anatomy. This warranty is the first facility risk-share agreement on titanium-enhanced PEEK interbody in the spine industry.
